Cytokinetics, Incorporated (CYTK) Ownership
CYTK ownership summary
as of October 18, 2026- Institutions
- 125.9% of shares outstanding
- Insiders
- 0.57% of shares outstanding
- Shares outstanding
- 139.0M
- Float
- 138.5M shares available to trade
- Short interest
- 21.23% 19.3M shares short
- Days to cover
- 9.28 short interest up 10.6% vs prior month
- Institutions 125.86%
- Insiders 0.57%
CYTK top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | BlackRock Inc | 14.45% | 20.1M | $1.24B | +3.5M (+21.4%) | June 30, 2026 |
| 2 | T. Rowe Price Investment Management,Inc. | 13.46% | 18.7M | $1.16B | +1.2M (+6.8%) | June 30, 2026 |
| 3 | Wellington Management Company LLP | 4.99% | 6.9M | $429.4M | −1.1M (−13.5%) | June 30, 2026 |
| 4 | Vanguard Portfolio Management, LLC | 4.83% | 6.7M | $415.8M | +868,017 (+14.9%) | June 30, 2026 |
| 5 | State Street Corp | 4.67% | 6.5M | $402.3M | +749,040 (+13.0%) | June 30, 2026 |
| 6 | Vanguard Capital Management, LLC | 4.40% | 6.1M | $379.0M | +628,881 (+11.5%) | June 30, 2026 |
| 7 | FMR Inc | 3.62% | 5.0M | $311.7M | −5.7M (−53.1%) | June 30, 2026 |
| 8 | venBio Select Advisor LLC | 3.60% | 5.0M | $309.7M | +1.7M (+50.0%) | June 30, 2026 |
| 9 | Bank of America Corp | 3.33% | 4.6M | $287.2M | +1.5M (+48.3%) | June 30, 2026 |
| 10 | Geode Capital Management, LLC | 2.67% | 3.7M | $230.0M | +497,086 (+15.5%) | June 30, 2026 |
| 11 | RTW INVESTMENTS, LLC | 2.06% | 2.9M | $177.3M | +140,845 (+5.2%) | June 30, 2026 |
| 12 | Polar Capital Holdings PLC | 1.62% | 2.3M | $139.6M | +592,401 (+35.7%) | June 30, 2026 |
| 13 | T. Rowe Price Associates, Inc. | 1.41% | 2.0M | $121.4M | +374,625 (+23.6%) | June 30, 2026 |
| 14 | The Goldman Sachs Group Inc | 1.27% | 1.8M | $109.1M | −444,170 (−20.1%) | June 30, 2026 |
| 15 | Capital Research Global Investors | 1.21% | 1.7M | $104.5M | +915,626 (+118.8%) | June 30, 2026 |
| 16 | Northern Trust Corp | 1.18% | 1.6M | $102.1M | +205,711 (+14.3%) | June 30, 2026 |
| 17 | William Blair Investment Management, LLC | 1.15% | 1.6M | $99.3M | +515,851 (+47.4%) | June 30, 2026 |
| 18 | Integral Health Asset Management, LLC | 1.15% | 1.6M | $99.1M | — | June 30, 2026 |
| 19 | JPMorgan Chase & Co | 1.14% | 1.6M | $98.4M | +685,090 (+75.8%) | June 30, 2026 |
| 20 | Point72 Asset Management, L.P. | 1.14% | 1.6M | $98.4M | +961,610 (+153.6%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 16 holders added 15.1M shares and 3 cut 7.2M.
CYTK top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | T. Rowe Price Capital Appreciation | 4.52% | 6.3M | $389.4M | — | August 31, 2026 |
| 2 | iShares Core S&P Mid-Cap ETF | 3.56% | 5.0M | $306.8M | −1,764 (−0.0%) | September 30, 2026 |
| 3 | Vanguard MStar Total Stk Mkt Idx Invest | 3.11% | 4.3M | $267.9M | −5,200 (−0.1%) | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 2.51% | 3.5M | $216.3M | −40,256 (−1.1%) | September 30, 2026 |
| 5 | Vanguard Small Cap Index | 2.25% | 3.1M | $193.6M | +5,399 (+0.2%) | August 31, 2026 |
| 6 | Vanguard Health Care Inv | 2.23% | 3.1M | $192.4M | −958,847 (−23.6%) | June 30, 2026 |
| 7 | American Funds SMALLCAP World A | 2.16% | 3.0M | $185.7M | +882,153 (+41.7%) | June 30, 2026 |
| 8 | Fidelity OTC | 1.59% | 2.2M | $137.1M | −56,200 (−2.5%) | August 31, 2026 |
| 9 | State Street® SPDR® S&P® Biotech ETF | 1.44% | 2.0M | $124.3M | −38,200 (−1.9%) | September 30, 2026 |
| 10 | Polar Capital Biotech S Inc | 1.30% | 1.8M | $112.1M | +214,576 (+13.5%) | August 31, 2026 |
| 11 | Vanguard MStar Small Cap Growth Indx Inv | 1.29% | 1.8M | $111.1M | −12,801 (−0.7%) | August 31, 2026 |
| 12 | T. Rowe Price Small-Cap Value | 1.19% | 1.7M | $102.9M | +606,255 (+57.5%) | August 31, 2026 |
| 13 | JNL/T. Rowe Price Capital Appreciation A | 1.04% | 1.4M | $89.6M | +345,478 (+31.4%) | June 30, 2026 |
| 14 | Fidelity Small Cap Index | 1.04% | 1.4M | $89.5M | +11,809 (+0.8%) | July 31, 2026 |
| 15 | T. Rowe Price Mid-Cap Growth | 1.04% | 1.4M | $89.3M | −625 (−0.0%) | August 31, 2026 |
| 16 | T. Rowe Price Capital Apprec Eq ETF | 0.94% | 1.3M | $80.7M | +1,560 (+0.1%) | September 30, 2026 |
| 17 | iShares Russell 2000 Value ETF | 0.81% | 1.1M | $69.9M | +1,710 (+0.2%) | September 30, 2026 |
| 18 | Polar Capital Healthcare Opports Inc | 0.77% | 1.1M | $66.0M | — | August 31, 2026 |
| 19 | iShares Biotechnology ETF | 0.75% | 1.0M | $64.5M | −7,888 (−0.8%) | September 30, 2026 |
| 20 | State Street® SPDR® S&P MIDCAP 400® ETF | 0.71% | 993K | $61.5M | −11,180 (−1.1%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
CYTK insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-21 | Fady Ibraham Malik | Sell | $65.69 | 3,500 | $229,915 |
| 2026-04-15 | Robert I Blum | Sell | $65.38 | 7,500 | $490,350 |
| 2026-04-15 | Andrew Callos | Sell | $66.02 | 7,449 | $491,783 |
| 2026-04-07 | Fady Ibraham Malik | Sell | $65.11 | 4,500 | $292,995 |
| 2026-03-18 | Andrew Callos | Sell | $62.07 | 1,930 | $119,795 |
| 2026-03-17 | Andrew Callos | Sell | $62.15 | 8,542 | $530,885 |
| 2026-03-17 | Fady Ibraham Malik | Sell | $62.15 | 12,033 | $747,851 |
| 2026-03-17 | Robert I Blum | Sell | $62.15 | 36,601 | $2.3M |
| 2026-03-17 | Sung Lee | Sell | $62.15 | 4,935 | $306,710 |
| 2026-03-16 | Andrew Callos | Sell | $61.03 | 1,709 | $104,300 |
| 2026-03-09 | Andrew Callos | Sell | $60.72 | 2,582 | $156,779 |
| 2026-03-09 | Robert I Blum | Sell | $60.72 | 7,931 | $481,570 |
| 2026-03-09 | Fady Ibraham Malik | Sell | $60.72 | 2,907 | $176,513 |
| 2026-03-05 | Andrew Callos | Sell | $61.87 | 26,000 | $1.6M |
| 2026-02-05 | Andrew Callos | Sell | $61.93 | 15,000 | $928,950 |
| 2026-02-02 | Andrew Callos | Sell | $62.10 | 886 | $55,021 |
| 2026-01-05 | Andrew Callos | Sell | $60.28 | 15,000 | $904,200 |
| 2026-01-02 | Andrew Callos | Sell | $62.62 | 1,798 | $112,591 |
| 2025-12-29 | Andrew Callos | Sell | $62.44 | 1,809 | $112,954 |
| 2025-12-22 | Wendell Wierenga | Sell | $66.14 | 20,000 | $1.3M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
CYTK shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns CYTK
Institutional investors own 125.9% of Cytokinetics's shares and insiders 0.57%. The largest holder is BlackRock Inc with 14.45% of the shares (20.1M), as of June 30, 2026. Among the top 20 institutions, 16 added shares and 3 reduced their stake in the latest filings. Short interest is 21.23% of the float, or 9.28 days of average trading volume. The share count rose 232.8% since 2014.
Related: CYTK analyst forecast, CYTK key metrics. See the CYTK stock overview for the latest quote and news.
CYTK ownership FAQ
Who owns the most Cytokinetics stock?
The largest shareholders of Cytokinetics are BlackRock Inc (14.45%), T. Rowe Price Investment Management,Inc. (13.46%), Wellington Management Company LLP (4.99%), Vanguard Portfolio Management, LLC (4.83%), State Street Corp (4.67%).
What percentage of Cytokinetics is owned by institutions?
Institutions hold 125.9% of Cytokinetics's shares outstanding; insiders hold 0.57%.
Which funds own Cytokinetics?
The largest fund holders of Cytokinetics are T. Rowe Price Capital Appreciation (4.52%), iShares Core S&P Mid-Cap ETF (3.56%), Vanguard MStar Total Stk Mkt Idx Invest (3.11%), iShares Russell 2000 ETF (2.51%), Vanguard Small Cap Index (2.25%).
What is Cytokinetics's short interest?
19.3M shares of Cytokinetics were sold short, 21.23% of the float; at the average daily volume it would take 9.28 days to cover.
Are insiders buying or selling Cytokinetics?
Of the latest 20 reported insider transactions in Cytokinetics (since December 22, 2025), 0 were purchases and 20 were sales.
How many shares of Cytokinetics are outstanding?
Cytokinetics has 139.0M shares outstanding, of which 138.5M are in the public float.